|
We seek investments in Life Science companies in three principal areas: Drug Development, Medical Devices, and Healthcare Services. We consider business plans from experienced entrepreneurs passionately pursuing disruptive opportunities that fulfill large unmet medical or market needs.
Integra's strategy is to develop a portfolio of outstanding regional and national biomedical companies chosen within the framework of our partner's extensive biomedical, service and device expertise.
This will be executed through:
1. Classic venture investing in seed through A & B rounds.
2. Later stage and workout investing through Series C and D rounds of financing, growth equity investments and recapitalizations.
Collectively our partners have nearly a century of broad based life science experience in: basic scientific discovery, clinical care, medical device inventions, entrepreneurial start ups, and board leadership. Each of us has executive level start-up entrepreneurial experience.
We are value investors. As such, we have established a reputation for identifying unique situations where the market has not yet fully recognized the value inherent in a company's technology or IP. We have been successful in identifying such opportunities in large company spin-outs of non-core technology, in companies that have financed technology development through grant funding or other forms of non-dilutive equity, and in recapitalizations/ restructurings of venture backed companies.
Though we seek opportunities on a national basis, we focus our activities on the west coast, particularly in the Northwest. We prefer to invest as part of a syndicate, partnering with firms that also have technical or market expertise, capital depth, and/or strategic influence. We have led nearly one half of our deals in early-stage companies, as well as followed other funds in later-stage opportunities.
We are highly engaged in the growth and development of our portfolio companies. We recognize that technology is only as good as the people who manage it, and we look for a management team that has "been there, done that" and who share our commitment to excellence. We will partner with people who we respect, and who share our values. Their business must meet the needs of our complex health system and its constituents, with discipline and consistency, over a substantial period of time.
We view each of our investments as a partnership between our team, our co-investors, and company management. We will normally seek a board seat or an observer role.
We seek to work with entrepreneurs who are not looking for a quick infusion of cash but who welcome the active support, expertise and enthusiasm that we bring to our portfolio companies, and who appreciate our commitment to our investors.
|
|
Prescription Drugs
for Half the Price: Wellpartner Smooths Way for Clinics to Buy Them
November 5, 2008
Targeted Growth
Sees Future In Your Breakfast Bowl
September 11, 2008
Wellpartner
Looks To Grow With $16M Series D
August 5, 2008
MediQuest
Vying to Get First Drug Across FDA Goal Line, Put Raynaud’s in Your Vocabulary
July 15, 2008
Blue
Heron Strives to Replace Gene-Making Grunt Work with Custom Manufacturing
June 18, 2008
Tepha
Announces First Human Usage of Medical Devices Derived from New
Class of Resorbable Polymers
April 17, 2008
Millipore, Guava
to Integrate Flow Cytometry Reagents, Instrumentation
March 04, 2008
Higher crop yields, more biofuel
November 19, 2007
Patent Awarded to MediQuest
Therapeutics
October 29, 2007
Integra portfolio company
Blue Heron Biotechnology featured in NYT Article
September 12, 2007
see more news
|
